Michele Reni

Biography

Dr. Michele Reni is the director of the Strategic Clinical Coordination Programme of the Pancreas Centre of IRCCS Ospedale San Raffaele and referent of outpatient activities focused on the treatment of pancreatic, nervous system and gastro-oesophageal tumours at the Oncology Medicine Department, under the direction of Prof. Stefano Cascinu.

He graduated from the Faculty of Medicine and Surgery of the University of Milan in 1988, specialized in Radiation Therapy in 1992 and received a second specialization in Medical Oncology in 1996.

Both clinically and in research, Dr Reni is interested in the treatment of pancreatic, nervous system, gastric and oesophageal tumours. In particular, his main contribution has been to co-ordinate more than 20 independent studies that have led to changes in standard therapy for pancreatic cancer.

He is the coordinator of the pancreatic cancer treatment guidelines and the drafter of the central nervous system tumor treatment guidelines of the Italian Association of Medical Oncology. He is also the member of the Board of Directors of the Italian Association for the Study of the Pancreas (AISP).

He has authored and co-authored more than 200 publications in peer-reviewed journals and book chapters. His Hirsch index is 49. He regularly participates as a lecturer in national and international industry congresses.

Education

University of Milan

Degree in Medicine and Surgery - 1988

University of Milan

Specialization in Radiotherapy - 1992

University of Milan

Specialization in Medical Oncology - 1996

Do you need an appointment?

Contact us and we will take care of you.

Publications

Latest publications

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Br J Cancer. 2016 Jul 26;115(3):290-6.
Reni M, et al.
Read more
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol. 2016 17 (11): 1521- 1532.
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe
Read more
Health-related quality of life in patients with high-risk lowgrade glioma (EORTC 22033-26033): a randomised, openlabel, phase 3 intergroup study.
Lancet Oncol. 2016; 17 (11): 1533-1542
Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG
Read more
What treatment in 2017 for inoperable pancreatic cancers?
Ann Oncol. 2017
Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M.
Read more
Central nervous system gliomas. Crit Rev Oncol Hematol.
2017 May;113:213-234
Reni M, Mazza E, Zanon S, Gatta G, Vecht CJ
Read more
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.
Ann Oncol. 2017;28(11):2786-2792
Reni M, et al.
Read more
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.
Cancer Treat Rev. 2017;60:32-43
Chiaravalli M, Reni M, O'Reilly EM.
Read more
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Lancet Oncol. 2018 Mar;19(3):e151-e160
Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Oldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van
Read more
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423.
Reni M, et al
Read more
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Semin Oncol. 2018 Jun;45(3):107-115.
Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG
Read more
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Lancet Gastroenterol Hepatol. 2018;3(10):691-697
Reni M, et al
Read more
A randomised phase 2 trial of nabpaclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Eur J Cancer. 2018;102:95-102
Reni M, et al
Read more
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.
Cancer Treat Rev. 2019;72:1-6.
Macchini M, Chiaravalli M, Zanon S, Peretti U, Mazza E, Gianni L, Reni M.
Read more
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
NEJM 2019
Golan T, Hammel P, Reni M, et al
Read more

Do you need an appointment?

Contact us and we will take care of you.